Drugs / Helminth ova
Helminth ova
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00645749 | Jul 2008 → Aug 2015 | relapsing-remitting multiple sclerosis | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Helminth ova | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00645749 ↗ |
| Known as | Trichuris suis | “BACKGROUND: Probiotic treatment strategy based on the hygiene hypothesis, such as administration of ova from the non-pathogenic helminth, Trichuris suis, (TSO) has proven safe...” PMID 21372112 ↗ Mar 2011 |
| Known as | TSO | “BACKGROUND: Probiotic treatment strategy based on the hygiene hypothesis, such as administration of ova from the non-pathogenic helminth, Trichuris suis, (TSO) has proven safe...” PMID 21372112 ↗ Mar 2011 |
| Modality | Other / unclassified | “probiotic helminth administration” PMID 21372112 ↗ Mar 2011 |
| Route | Oral | “Five subjects with newly diagnosed, treatment-naive relapsing-remitting multiple sclerosis (RRMS) were given 2500 TSO orally every 2 weeks for 3 months” PMID 21372112 ↗ Mar 2011 |